Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tech Transfer Roundup: Academia's Role In De-Risking Novel Science

Executive Summary

The Sanford Burnham Prebys institute is driving innovation in areas like neurodegenerative disease and immuno-oncology. Plus the latest tech transfer deals: two in cancer, one in asthma/allergies and another in lipid nanoparticle technology.

You may also be interested in...



Tech Transfer Roundup: Tonix Obtains Triple-Reuptake Inhibitor For PTSD From Wayne State

TNX-1600 joins two other candidates, including Phase III TNX-102 SL, in Tonix’s PTSD portfolio. CureVac and Yale partner on mRNA therapies for pulmonary disease.

Pfizer Inks Diabetes Discovery Collaboration With Sanford-Burnham

The New York-based pharma continues to delve further into the diabetes research space despite not currently having a commercial presence in the therapeutic area. Pfizer’s latest tie-up will help it identify targets that could be used in the treatment of diabetes and obesity.

Sobi Loses Private Equity Buyout

An $8bn public-to-private takeout by two private equity firms of the Swedish rare disease specialist collapses because total tenders to the offer fell below a 90% threshold.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC098850

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel